Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
Ligand PharmaceuticalsAbbVie
Last price
$297.70$282.85
Currency
USD
USD
$5.9B$504B
32.1580.63
$9.19$3.54
0.980.28
0$6.83
02.42%
Sector
HealthHealth
Employees
4757,000
Ticker
$LGND$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $LGND or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.